Clinical Trial Search

Primary: Percentage Change in Palmoplantar Pustulosis Severity Index (PPPASI) Before Crossover — 30.1; 7.1 Percentage change

Primary: 75% Improvement in Modified Palmoplantar Pustulosis Area and Severity Index (m-PPPASI) From Day 0 — 1; 4 Participants

Primary: Percentage of Participants Achieving Palmoplantar Investigator's Global Assessment (ppIGA) of "Clear" or "Almost Clear" (0 or 1) With at Least a 2-point Reduction From…

Primary: Mean Percent Change of mNAPSI (Modified Nail Area Psoriasis Severity Index) at Week 36 Compared to Baseline for All Nails. — 64.1 percentage of reduction in mNAPSI score…

Primary: Study-G: Percentage of Participants With Achievement of Static Physician Global Assessment of Genitalia (sPGA-G) of 0 or 1 at Week 16 — 13.0; 69.1 percentage of…

Primary: Number of Participants With Serious Infections, Opportunistic Infections of Interest and Malignancies: Prospective Participants — 0; 0; 0 Participants

Primary: Modified NAPSI Score (Nail Psoriasis Severity Index) — 6.3; 6.0 units on a scale

Primary: The Change in the Psoriasis Area and Severity Index (PASI) From Baseline to 16 Weeks in Psoriasis Patients With Type 2 Diabetes Treated With Sitagliptin Compared to…

Primary: Change in Histology

Primary: Percentage of Participants With ppPASI 75 Response at Week 16 (Period 1) — 17.5; 26.6; 14.1 percentage of participants — p=0.5722

Primary: Percentages of Participants With Palmoplantar Investigator Global Assessmnet (ppIGA) 0 or 1 Response After 16 Weeks of Treatment — 22; 33.3; 1.5 Percentages of…

Primary: Severity of Psoriasis — 2.68; 1.84 units on a scale

Primary: Palmoplantar Psoriasis Physician Global Assessment (PPPGA) of 0 or 1 — 7; 2 Participants

Primary: Change From Baseline in Palmoplantar Pustulosis Area and Severity Index (PPPASI) Total Score at Week 16 — -7.79; -15.08; -11.07 Units on a scale — p=<0.001

Primary: Log Transformed Ratio of Postbaseline Fresh Pustule Count at Day 28 to Baseline — 0.86; 0.53 Log transformed ratio — p=0.24